Helping Patients Navigate the Cefepime Shortage

When Cefepime is in short supply, the burden often falls on patients — many of whom are already managing serious infections — to figure out where to get their medication. As a provider, you're in a unique position to guide them through this process and ensure that treatment isn't delayed.

This guide offers a practical, step-by-step approach to helping your patients find Cefepime in stock, identify alternatives when needed, and streamline your shortage workflow.

Current Cefepime Availability

Cefepime injection has been subject to intermittent shortages for over a decade. The market is entirely generic (the brand name Maxipime was discontinued), with supply coming from manufacturers including Hospira/Pfizer, Baxter, B. Braun, Hikma, Apotex, and Sagent.

Key factors affecting current availability:

• Formulation variability: Premixed IV bags (1 g/50 mL, 2 g/100 mL) may be harder to source than powder vials (500 mg, 1 g, 2 g)
• Distributor allocations: Major distributors may limit orders based on historical purchasing patterns, which can disadvantage smaller facilities or new accounts
• Regional differences: Supply varies by geography and distributor network

Real-time availability data is accessible through Medfinder for Providers.

Why Patients Can't Find Cefepime

Understanding the barriers your patients face helps you provide better guidance:

• It's not a retail pharmacy drug: Most patients are accustomed to picking up medications at CVS or Walgreens. Cefepime is a sterile injectable that's dispensed through hospital pharmacies, specialty pharmacies, and home infusion providers — channels many patients don't know how to access.
• Insurance complexity: Outpatient IV antibiotics may be covered under medical benefits (not pharmacy benefits), requiring different authorization processes that patients may not understand.
• Limited information: Patients may not know which pharmacies carry injectable antibiotics or how to check availability.
• Cost barriers: Without insurance, a course of Cefepime can cost $90–$365 or more. Even with insurance, outpatient infusion copays can be significant.

What Providers Can Do: 5 Practical Steps

Step 1: Coordinate Early With Pharmacy

Before discharge or at the point of prescribing outpatient Cefepime, contact your pharmacy team to verify current stock levels and availability. For OPAT (outpatient parenteral antibiotic therapy) patients, loop in the home infusion pharmacy early in the discharge planning process — ideally 24–48 hours before the patient needs the medication.

Hospital pharmacists often have the most current information on which formulations are available and which manufacturers are shipping. They can also recommend therapeutic alternatives if supply is critically low.

Step 2: Direct Patients to Medfinder

Share Medfinder for Providers with your patients as a resource for locating Cefepime. Patients can search by medication name and location to see which pharmacies and infusion centers near them currently have it in stock.

Consider including Medfinder information in your discharge instructions or patient handouts for anyone being sent home on IV antibiotics during a shortage period.

Step 3: Connect With Home Infusion Providers

Home infusion pharmacies specialize in sourcing and dispensing injectable medications and often have access to supply channels that hospital and retail pharmacies don't. If your patient is appropriate for home IV therapy, connecting them with a home infusion provider can improve both access and continuity of care.

Maintain a current list of home infusion providers in your area and their contact information. Your social work or case management team may already have these relationships established.

Step 4: Consider Formulation Flexibility

If premixed Cefepime bags are unavailable, powder vials may still be in stock (or vice versa). Work with your pharmacy team to determine whether a different formulation can meet the patient's needs. For home infusion patients, the pharmacy can often reconstitute vials into ready-to-use solutions.

Similarly, if a specific dose strength is unavailable (e.g., 2 g vials are out but 1 g vials are available), pharmacists can adjust preparations accordingly.

Step 5: Communicate the Plan Clearly

Patients who are anxious about a drug shortage need clear, direct communication about their treatment plan. Tell them:

• What you're prescribing and why
• Where they should go to get it
• What to do if they can't find it
• Who to call with questions (your office, the pharmacy, or both)

Providing a written action plan — including the name of the medication, the pharmacy or infusion center, and a backup contact — reduces the chance of treatment gaps.

Alternative Antibiotics to Consider

When Cefepime cannot be sourced, the following alternatives may be appropriate depending on the clinical scenario:

• Piperacillin-Tazobactam (Zosyn): Comparable outcomes for pneumonia and febrile neutropenia. Provides anaerobic coverage. Monitor for AKI when combined with Vancomycin.
• Ceftazidime: Third-generation cephalosporin with strong anti-Pseudomonal activity. Less gram-positive coverage — may need to add Vancomycin or similar agent.
• Meropenem: Broadest coverage option. Reserve for resistant organisms or when narrower agents are unavailable. Dose adjust for renal function.
• Imipenem-Cilastatin: Broad-spectrum carbapenem. Avoid in patients with seizure history due to lower seizure threshold compared to Meropenem.
• Cefepime-Enmetazobactam (Exblifep): Newer combination product approved for complicated UTIs. May be an option for specific indications when standard Cefepime is unavailable.

For a patient-facing overview of these alternatives, share Alternatives to Cefepime If You Can't Fill Your Prescription.

Workflow Tips for Shortage Management

• Establish an institutional shortage protocol: Work with your antimicrobial stewardship team to develop pre-approved alternative therapy guidelines for Cefepime shortages. Having these in place before a shortage occurs saves time and reduces variability in care.
• Monitor ASHP and FDA shortage databases: Subscribe to alerts from ASHP and the FDA Drug Shortage Database for early warning of supply disruptions.
• Audit Cefepime usage: During shortages, review current patients on Cefepime to identify opportunities for de-escalation or conversion to oral therapy. This frees up supply for patients who truly need IV Cefepime.
• Coordinate across departments: Infectious disease, pharmacy, case management, and nursing should communicate regularly about shortage status and patient needs.
• Document shortage-related decisions: When a shortage drives a change in therapy, document the clinical rationale in the patient's chart. This supports clinical decision-making and can help with insurance appeals if needed.

Final Thoughts

Drug shortages are a systemic problem, but their impact is felt one patient at a time. By planning ahead, leveraging tools like Medfinder for Providers, and communicating clearly with patients and pharmacy teams, you can minimize treatment disruptions and ensure your patients get the care they need.

For a broader overview of the current shortage situation, see Cefepime Shortage: What Providers and Prescribers Need to Know in 2026.